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Occult hepatitis B virus (HBV) infection
Isolated hepatitis B core antibody (anti-
HBc)
A B S T R A C T
Background: Occult hepatitis B virus (HBV) infection in blood donors is considered a potential threat for
the safety of the blood supply, however conclusive studies on this issue are lacking. The aim of this study
was to assess the occult HBV infection in blood donors with isolated hepatitis B core antibody (anti-HBc)
living in the city of Arak, in the Central Province of Iran, as a low prevalence region for HBV.
Methods: A total of 531 voluntary blood donors in Arak, Iran were included in this study. Hepatitis B
surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs), anti-HBc, and hepatitis C antibody
(anti-HCV) were tested in all subjects. The presence of HBV-DNA was determined quantitatively in
plasma samples of cases with isolated anti-HBc (HBsAg-negative, anti-HBs-negative, and anti-HBc-
positive) by real-time PCR using the artus HBV RG PCR kit on the Rotor-Gene 3000 real-time thermal
cycler.
Results: Of 531 subjects enrolled in this study, 11 (2.1%, 95% confidence interval 0.8–3.2%) had isolated
anti-HBc. HBV-DNA was not detected in any of the cases with isolated anti-HBc.
Conclusions: Our study showed that all the blood donors with isolated anti-HBc were negative for HBV-
DNA, and occult HBV infection did not occur in the blood donors of this low prevalence region for HBV
infection.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Infection with the hepatitis B virus (HBV) is a serious global
health problem, with two billion people infected worldwide and
350 million suffering from chronic HBV infection. Of these, 75% are
Asians.1 Among the many transmission routes, transfusion is the
one that could be prevented. The first major success in enhancing
transfusion safety came with the implementation of hepatitis B
surface antigen (HBsAg) detection in the early 1970 s. However,
studies have demonstrated that transmission by HBsAg-negative
blood components can still occur in the acute phase of infection
during the seronegative window period, or during chronic stages of
infection with undetectable HBsAg.2
With the development of sensitive assays to detect HBV-DNA it
has been shown that healthy HBsAg-negative donors who have
antibodies to HBV core antigen (anti-HBc) may harbor an occult* Corresponding author. Tel.: +98 21 66968852; fax: +98 21 66465147.
E-mail address: iiccom@iiccom.com (A. Ramezani).
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doi:10.1016/j.ijid.2009.05.011HBV infection and maintain HBV-DNA sequences in their liver and
blood, thus representing potential sources of HBV transmission.3–5
The serological pattern defined as isolated anti-HBc (HBsAg-
negative, hepatitis B surface antibody (anti-HBs)-negative, and
anti-HBc-positive) is observed in 10–20% of individuals from areas
of low endemicity for HBV.6 The significance of this serological
pattern is unclear. It may reflect past infection with HBV, after
which anti-HBs either did not develop7 or decreased to an
undetectable level.6 Also, this serological pattern can be observed
in the window phase of a resolving case of acute hepatitis B. Finally
it may represent occult chronic HBV infection, with levels of the
HBsAg below the limits of detection.8
Detection of HBV-DNA without detectable HBsAg is defined as
occult HBV infection.9,10 The frequency of detection of occult HBV
infection depends on the relative sensitivity of both HBsAg and
HBV-DNA assays. It also depends on the prevalence of HBV
infection in the population.11 The prevalence of occult HBV
infection is higher in areas in which HBV infection itself is more
frequent. Iran is in the low endemic area for HBV.12 The prevalence
of HBsAg in Iran ranges from 1.7% to over 5% in the differentses. Published by Elsevier Ltd. All rights reserved.
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HBV is estimated to be 0.5%. It is estimated that 7500–15 000
chronic HBV individuals live in this province, which has a
population of 1.5 million.15
Anti-HBc screening of blood donations is controversial and
variably performed in different countries.16 With regard to
transfusion, anti-HBc screening has been used initially as a
surrogate marker for non-A, non-B hepatitis, and its screening
can potentially prevent occult HBV transmission.17 Occult HBV
infection in blood donors is considered a potential threat for the
safety of the blood supply, however conclusive studies on this issue
are lacking.11
The aim of the present study was to assess the occult HBV
infection in blood donors presenting with the serological pattern of
isolated anti-HBc, living in Arak City, in the Central Province of Iran,
as a low prevalence region for HBV.
2. Patients and methods
The blood samples used in this study were collected from the
Arak Blood Transfusion Organization in Arak City, in the Central
Province of Iran between October and December 2008. A total of
531 blood donors out of the 7200 were randomly enrolled in this
study. A questionnaire was used to collect data such as age and sex.
This project was approved by the Iranian Society for the Support of
Patients with Infectious Diseases ethics committee, and informed
consent was obtained from patients prior to their enrollment.
Blood samples were collected from all patients and plasma was
stored at80 8C. All patients were tested for HBsAg, anti-HBs, anti-
HBc, and hepatitis C antibody (anti-HCV) by ELISA. The commercial
enzyme immunoassay kits used were as follows: HBsAg, anti-HBs
and anti-HCV (Enzygnost, Dade Behring, Marburg GmbH, Ger-
many) and anti-HBc (Enzywell, Diesse.Tec Diagnostica, Monter-
iggioni (Siena), Italy). All anti-HBc-positive samples were re-tested
with the same assay.
HBV-DNA was extracted using the High Pure Viral Nucleic
Acid kit (Roche Diagnostics GmbH, Mannheim, Germany)
following the manufacturer’s instructions. HBV-DNA was deter-
mined quantitatively by real-time PCR using the artus HBV RG
PCR kit (Qiagen, Hamburg, Germany) on the Rotor-Gene 3000
real-time thermal cycler (Corbett Research, Sydney, Australia).
According to the user manual, the analytical detection limit of
the kit is 0.02 IU/ml.
3. Statistical analysis
Chi-square and t2 tests were used with SPSS v. 16 for statistical
analysis (SPSS Inc., Chicago, IL, USA). Data are presented as
mean  standard deviation (SD) or, when indicated, as an absolute
number and percentage. The 95% confidence interval (95% CI) was
calculated.
4. Results
A total of 531 voluntary blood donors living in the city of Arak,
in the Central Province of Iran, with a mean age of 36  10.18 years
(range 16–60 years) were enrolled in the study. Ninety-three percent
of patients were male and 7% were female. HBsAg, anti-HBs, anti-HBc,
and anti-HCV were found in 0.4%, 31.8%, 11.5%, and 0.2% of subjects,
respectively. Of the 531 cases, 11 subjects (2.1%, 95% CI 0.8–3.2%) had
isolated anti-HBc.
HBV-DNA was not detected in any of the cases with isolated
anti-HBc. All HBV-DNA-negative samples underwent confirmatory
testing with additional real-time PCR on the same nucleic acid
extracted material, but all of the samples were repeatedly negative
for HBV-DNA.5. Discussion
In this study we investigated the frequency of HBV-DNA in
HBsAg- and anti-HBs-negative, anti-HBc-positive blood samples
collected from voluntary blood donors living in the city of Arak in
the Central Province of Iran, where HBV prevalence is low. This
survey showed that the prevalence of isolated anti-HBc and HBV-
DNA was negligible in blood donors in this region.
In published studies, the prevalence of anti-HBc in HBsAg-
negative blood donors ranges from 0.56% in the UK,18 0.84% in the
USA,19 1.4% in Germany,4 15.03% in Greece,20 and 16.4% in Saudi
Arabia,21 to 76% in Ghana.18
Occult HBV infection is most frequently seen in patients with
anti-HBc as the only HBV serological marker.22 When detectable,
the amount of HBV-DNA in the serum is usually very low (<200 IU/
ml).23 Occult HBV infection in blood donors is considered a
potential threat for the safety of the blood supply. A number of
explanations for the persistence of HBV-DNA in HBsAg-negative
samples have been proposed, including the presence of HBV-DNA
at a low copy number,9 genetic variations in the S gene,24,25 and the
presence of immune complexes in which HBsAg may be
hidden.26,27 Occult hepatitis B may also be due to the window
period following acute HBV infection, poor laboratory detection of
HBsAg due to low levels of HBs antigenemia, underlying HCV co-
infection, immunosuppression, or other host factors.6,28 Moreover,
it has been suggested recently that HIV infection may be a risk
factor for occult hepatitis B.29,30
The relative proportion of occult HBV is likely to be related to
local epidemiology, composition of the study populations, and the
level of sensitivity of the HBV-DNA assay.
The percentage of samples containing HBV-DNA from either
blood donors or the general population ranges between 0% and
7.7% in areas in which the prevalence of HBV is low.4,19,31 In areas
of higher HBV infection prevalence, such as Greece (15.8%), China
(70.0%), and Ghana (83.6%), the frequency of DNA-positive isolated
anti-HBc cases increases to 1.9%, 2.7%, and 12.7%, respec-
tively.18,20,32
One large study investigated 6313 consecutive blood donors
and found that the prevalence of anti-HBc-positive subjects was
4.85%, and 4.86% of subjects were confirmed to have circulating
HBV-DNA at a low level. The sensitivity of the assay for HBV-DNA
was 4.9 IU/ml.33 A second study investigated 244 blood donors
with isolated anti-HBc and reported that all samples were negative
for HBV-DNA.34 In a study of 760 healthy Egyptian blood donors,
HBV-DNA was found in 11.54% of the anti-HBc-positive units.35
Garcı́a-Montalvo et al.36 investigated the sera of 158 volunteer
blood donors, negative for HBsAg and anti-HBs, but positive for
anti-HBc, using a nested PCR. Occult HBV infection was observed in
approximately 8% of anti-HBc only donors. The lower limit of
detection for the nested PCR assay was 30–300 copies of the viral
genome per ml. Duseja et al.37 studied 100 healthy adult blood
donors, negative for HBsAg, anti-HCV, HIV-1, and other risk factors
for HBV-DNA by PCR. All the healthy blood donors were negative
for HBV-DNA.
Kaminski et al.38 reported that 20.5% of HBsAg-negative blood
donors had anti-HBc only pattern and HBV-DNA was not detected
in any of these cases. Our results regarding occult HBV infection are
compatible with the results of the studies of Kaminski et al.,38
Duseja et al.,37 and Kupski et al.34 and are comparable to the rates
(0–7.7%) reported in regions in which the HBV prevalence among
blood donors is low.4,19,31
In a study by Behzad-Behbahani et al. in Fars Province of Iran, on
2000 healthy blood donors, 6.55% of blood samples were found to
be positive for anti-HBc. HBV-DNA was detected in 12.2% of anti-
HBc-positive specimens.39 In the Central Province of Iran, the
prevalence of HBV is estimated to be 0.5%.15 In Fars Province, in the
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healthy blood donors was about 1%.13 The discrepancy between
the study of Behzad-Behbahani et al. and our survey may be due to
local epidemiology, prevalence of HBV infection, and composition
of the study populations.
In conclusion, in this study all the blood donors with isolated
anti-HBc were negative for HBV-DNA, and occult HBV infection did
not occur in the blood donors in this low prevalence region for HBV
infection. However, due to the limited number of cases in the
present study, a definite conclusion cannot be reached regarding
the frequency of occult HBV infection in blood donors. Because of
the relationship of occult HBV with local epidemiology, further
studies on more cases in different populations are suggested to
determine whether anti-HBc screening should be implemented in
screening programs for HBV infection among blood donors in HBV
low-endemic areas.
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